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Sirtuins are nicotinamide adenine dinucleotide (NAD+)-dependent deacylases that have traditionally been
linkedwith calorie restriction and aging inmammals. These proteins also play an important role inmaintaining
neuronal health during aging. During neuronal development, the SIR2 ortholog SIRT1 is structurally impor-
tant, promoting axonal elongation, neurite outgrowth, and dendritic branching. This sirtuin also plays a
role in memory formation by modulating synaptic plasticity. Hypothalamic functions that affect feeding
behavior, endocrine function, and circadian rhythmicity are all regulated by SIRT1. Finally, SIRT1 plays pro-
tective roles in several neurodegenerative diseases including Alzheimer’s, Parkinson’s, and motor neuron
diseases, which may relate to its functions in metabolism, stress resistance, and genomic stability. Drugs
that activate SIRT1 may offer a promising approach to treat these disorders.Introduction
The mammalian sirtuins are deacylase proteins that have been
shown to regulate diverse cellular processes including aging,
inflammation, and stress resistance (Brunet et al., 2004; Imai
et al., 2000; Kaeberlein et al., 1999; Kim et al., 1999; North and
Verdin, 2004). These enzymes were originally identified as
genetic silencing factors in yeast (Klar et al., 1979; Rine et al.,
1979) and can act on histones and other substrates in the pres-
ence of nicotinamide adenine dinucleotide (NAD+) (Imai et al.,
2000; Landry et al., 2000; Smith et al., 2000).
The sirtuins are categorized as class III histone deacetylases
(HDACs) and the posttranslational modification of histone
substrates can modulate chromatin condensation and gene
transcription. Deacetylation of lysine residues is often asso-
ciated with transcriptional repression; however, many sirtuin
substrates are nonhistone proteins and several sirtuins do not
have deacetylase activity (Dokmanovic et al., 2007; Gregoretti
et al., 2004).
There are seven sirtuins in mammals with varied subcellular
localization and enzymatic activity (Frye, 1999, 2000). SIRT1,
SIRT2, and SIRT3 exhibit NAD-dependent deacetylase activity
(Imai et al., 2000; North et al., 2003; Onyango et al., 2002; Schwer
et al., 2002; Tanny et al., 1999). SIRT4 is an ADP-ribosyltransfer-
ase (Haigis et al., 2006), whereas SIRT5 has NAD-dependent
demalonylase, desuccincylase, and deacetylase activities (Du
et al., 2011; Nakagawa et al., 2009; Peng et al., 2011). SIRT6
was initially shown to have deacetylase and ADP-ribosyltransfer-
ase activities (Liszt et al., 2005; Michishita et al., 2008; Mos-
toslavsky et al., 2006) and more recently has been shown
to catalyze the hydrolysis of fatty acyl lysine residues, which
may affect protein secretion (Jiang et al., 2013). SIRT7 is an
NAD-dependent deacetylase (Barber et al., 2012; Vakhrusheva
et al., 2008).
The sirtuins reside in different subcellular compartments, influ-
encing their in vivo substrates and cellular functions. SIRT1 wasinitially described as a nuclear protein (Michishita et al., 2005)
that may also shuttle to the cytoplasm during neuronal differen-
tiation and neurite outgrowth (Hisahara et al., 2008; Sugino et al.,
2010; Tanno et al., 2007), tumor progression (Byles et al., 2010;
Noh et al., 2013; Wauters et al., 2013), and apoptosis (Jin et al.,
2007). SIRT2 is a cytoplasmic protein that can deacetylate
tubulin (North et al., 2003) but has also been described in the
nucleus during cell-cycle progression (North and Verdin, 2007),
cancer (Imaoka et al., 2012), and bacterial infection (Eskandarian
et al., 2013). SIRT3, SIRT4, and SIRT5 are mitochondrial sirtuins;
however, they each have distinct enzymatic activities within this
organelle (Du et al., 2011; Haigis et al., 2006; Nakagawa et al.,
2009; Hirschey et al., 2010). SIRT6 associates with chromatin
in the nucleus (Liszt et al., 2005; Mostoslavsky et al., 2006) and
is enriched in the nucleolus during the G1 phase of the cell cycle
(Ardestani and Liang, 2012), and SIRT7 is a nucleolar protein
(Ford et al., 2006).
Although there has been some controversy regarding the
functions of sirtuins in calorie restriction and aging, many recent
papers have reaffirmed the important roles of these proteins in
both processes (reviewed in Guarente, 2013). For example,
SIRT3 was shown to be essential for calorie restriction to protect
the neurons in the cochlea against oxidative damage and thus
forestall hearing loss in mice (Someya et al., 2010).
Sirtuins have been recently shown to have many important
functions during development, influencing brain structure
through axon elongation (Li et al., 2013), neurite outgrowth
(Sugino et al., 2010), and dendritic branching (Codocedo et al.,
2012), as well as cellular fate of neuronal precursor cells (Prozor-
ovski et al., 2008; Rafalski et al., 2013). These proteins also play a
major role in the hypothalamus, affecting circadian rhythmicity
(Asher et al., 2008; Bellet et al., 2011, 2013; Chang andGuarente,
2013; Nakahata et al., 2008, 2009), endocrine function (Cohen
et al., 2009), and feeding behaviors (Ramadori et al., 2011;
Sasaki et al., 2010; Satoh et al., 2010). In the adult brain, SIRT1Neuron 81, February 5, 2014 ª2014 Elsevier Inc. 471
Figure 1. The Influence of Sirtuin 1 on
Neuronal Architecture
The role of SIRT1 on structural features of neuronal
cells is depicted. SIRT1 can promote axon devel-
opment by deacetylating Akt and inhibiting Gsk3,
affecting microtubule dynamics during axon
elongation (Li et al., 2013). SIRT1 also interacts
with microRNA-138 via a negative feedback loop
and this microRNA suppresses axon growth (Liu
et al., 2013). SIRT1 also affects dendritic arbori-
zation (Micha´n et al., 2010) and dendritic spine
morphology by inhibition of ROCK kinase activity
(Codocedo et al., 2012). Cytoplasmic SIRT1
can stimulate NGF-dependent neurite outgrowth
(Hisahara et al., 2008; Sugino et al., 2010), which is
due to downregulation of mTOR and inhibition of
its downstream effectors (Guo et al., 2011).
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(Gao et al., 2010; Micha´n et al., 2010). In addition to its impor-
tance during normal brain aging, SIRT1 has also been shown
to ameliorate a number of neurodegenerative disorders including
Alzheimer’s (Donmez et al., 2010; Min et al., 2010; Qin et al.,
2006), Parkinson’s (Donmez et al., 2012;Mudo` et al., 2012), Hun-
tington’s disease (Jeong et al., 2012; Jiang et al., 2012), motor
neuron diseases (Han et al., 2012; Kim et al., 2007; Montie
et al., 2011), and multiple sclerosis (Fonseca-Kelly et al., 2012;
Shindler et al., 2007, 2010) in animal models of these diseases.
Current therapies for these neurologic disorders are not cura-
tive and there is great interest in targeting sirtuin pathways
pharmacologically.
Small molecules like resveratrol and synthetic SIRT1 activa-
tors were shown to activate the enzyme directly via an allosteric
site adjacent to the catalytic domain (Hubbard et al., 2013).
Although we discuss resveratrol throughout this Review, it is
important to remember the caveat that small molecules may
also hit non-SIRT1 neuronal targets to affect biological out-
comes in vivo. Resveratrol inhibits cAMP-degrading phos-
phodiesterases and activates the CamKKb-AMPK pathway by
increasing cAMP and activating Epac1. In addition to increasing
intracellular calcium levels, this pathway also increases NAD+
and SIRT1 activity (Park et al., 2012). SIRT2 inhibitors have
also been shown to be protective in animal models of Parkin-
son’s and Huntington’s diseases (Chopra et al., 2012; Outeiro
et al., 2007). In this Review, we will present an overview of
SIRT1 function in the brain during neurodevelopment, normal
aging, and neurodegenerative disease.472 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.Sirtuin 1 and Normal Brain Aging
Neuronal Structure
The early development of neurons begins
with neurite process elongation followed
by axon differentiation, dendritic arbori-
zation, and synapse formation (Codo-
cedo et al., 2012). Using cell culture
models and in utero electroporation,
SIRT1 has been shown to promote neu-
rite outgrowth and the subcellular locali-
zation of this deacetylase is critical for
its function (Figure 1). In PC12 cells, cyto-plasmic SIRT1 stimulates NGF-dependent neurite outgrowth;
however, this effect is abolished when nuclear localized con-
structs or catalytically inactive mutants are analyzed (Sugino
et al., 2010). A second study has confirmed and expanded on
these observations, reporting that SIRT1 briefly localizes to the
nucleus during differentiation from neuronal precursor cells
(NPCs) and SIRT1 inhibition decreases neurite length in culture
and in mouse brain after in utero electroporation (Hisahara
et al., 2008). A third study linked neurite outgrowth and neuronal
viability with the downregulation ofmammalian target of rapamy-
cin (mTOR) (Guo et al., 2011).
SIRT1 has also been shown to promote axon development in
embryonic hippocampal neurons. SIRT1 activates Akt, the up-
stream inhibitory kinase of glycogen synthase kinase 3 (GSK3),
and promotes axonogenesis in cultured hippocampal neurons
(Li et al., 2013). In embryonic cortical neurons, SIRT1 is the target
of microRNA-138, a small noncoding RNA that molecule sup-
presses axon growth (Liu et al., 2013). In response to peripheral
nerve injury, SIRT1 is also able to suppress miR-138, creating a
negative feedback loop.
Dendritic arborization is another important aspect of neuronal
development because the degree of branching affects the num-
ber of synaptic inputs that each neuron can integrate. SIRT1
knockout (KO) mice have been shown to have a reduced den-
dritic arbor but similar distribution of dendritic spines relative to
wild-type mice (Micha´n et al., 2010). A second study corrobo-
rated these findings in neuronal culture and also found that the
architecture of neuronal spines differed with SIRT1 overexpres-
sion and that SIRT1 catalytic activity was important for the
Figure 2. The Regulation of Learning and Memory by Sirtuin 1
In the hippocampus, SIRT1 affects synaptic plasticity via a repressor complex
containing the transcription factor YY1, which regulates microRNA-134 (mIR-
134). This brain-specific microRNA regulates cAMP response binding protein
(CREB) and brain-derived neurotrophic factor (BDNF) expression (Gao et al.,
2010). These proteins are important for synapse formation and long-term
potentiation. SIRT1 knockout mice have impaired hippocampal-dependent
memory that is associated with decreased long-term potentiation in the CA1
region of the hippocampus (Gao et al., 2010; Micha´n et al., 2010).
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nase activity (Codocedo et al., 2012). These studies support a
role for SIRT1 in the regulation and maintenance of dendritic
growth.
Learning and Memory
The development of synapses andmodulation of their strength is
important for memory formation and sirtuins play an important
role in this process. SIRT1 knockout animals have morphologic
alterations in neuronal structure, exhibiting dendrites with
decreased complexity and shorter branches by Golgi staining
(Micha´n et al., 2010). Studies using electron microscopy to
examine synaptic morphology show that inhibiting SIRT1 de-
creases synaptic inputs to hippocampal neurons (Dietrich
et al., 2010). Functionally, SIRT1 knockout mice have impaired
hippocampal-dependent memory that is associated with
decreased long-term potentiation in the CA1 region of the hippo-
campus. The expression of hippocampal genes was examined
by microarray analysis and genes for synaptic function, mem-
brane fusion, myelination, and metabolic function were altered
in knockout mice (Micha´n et al., 2010).
Brain-specific SIRT1 knockout mice have decreased syn-
aptic plasticity. SIRT1 interacts with a repressor complex con-
taining the transcription factor YY1 that regulates mIR-134 and
this brain-specific microRNA regulates cAMP response binding
protein (CREB) and brain-derived neurotrophic factor (BDNF)
expression (Gao et al., 2010). The relationship between SIRT1
and these targets is shown in Figure 2. A subsequent study
examining whether these alterations were reproducible using
a pharmacologic approach (with attending caveats for non-
SIRT1 effects) rather than genetic deletion found that levels of
miR-124 and miR-134 decreased after treatment with resvera-
trol (Zhao et al., 2013). Both CREB and BDNF increased while
memory formation and long-term potentiation (LTP) induction
improved in treated animals (Zhao et al., 2013).
Hypothalamic Function
The hypothalamus regulates physiology and behavior by sensing
metabolic changes and coordinating neuroendocrine responses
that modulate appetite, temperature, circadian control, and hor-
monal release tomaintain homeostasis (Coppari, 2012). SIRT1 is
expressed in several hypothalamic regions that regulate theresponse to food availability and circadian behaviors including
the arcuate (ARC), ventromedial (VMH), dorsomedial (DMH),
lateral hypothalamic (LH), and suprachiasmatic nucleus (SCN)
(Ramadori et al., 2008; Satoh et al., 2010). The role of SIRT1 in
these brain regions is illustrated in Figure 3.
The VMH nucleus regulates the balance between glucose and
insulin, and steroidogenic factor 1 (SF1)-expressing neurons
within this nucleus are particularly important for coordinating
the autonomic response to high-fat diet and obesity. SF1 neu-
rons express SIRT1 (Ramadori et al., 2011) and send excitatory
projections to pro-opiomelanocortin (POMC) cells in the arcuate
nucleus of the hypothalamus that release a-melanocyte-stimu-
lating hormone and cocaine-and-amphetamine-regulated tran-
script peptides to promote satiety (Coppari, 2012; Dietrich
et al., 2010). The arcuate nucleus also contains a second popu-
lation of neurons that inhibit POMC neurons, producing neuro-
peptide Y (NPY), agouti-related peptide (AgRP), and GABA to
promote feeding behaviors (Dietrich et al., 2010).
SIRT1 plays an important role in regulating neuronal function
in several hypothalamic regions. Mice that lack SIRT1 in SF1 or
POMC neurons have decreased energy expenditure and are
more sensitive to diet-induced obesity when fed high-fat diets
(Ramadori et al., 2010, 2011). Knocking out SIRT1 in hypotha-
lamic AgRP neurons decreases food intake (Dietrich et al.,
2010), an effect that is recapitulated when pharmacologic or
siRNA is used to inhibit SIRT1 nonspecifically in the hypothala-
mus, causing decreased weight and food intake (Cakir et al.,
2009). The mechanism for how SIRT1 regulates the feeding
response to caloric restriction is attributed to the deacetylation
of FOXO and may also affect mTOR/S6K signaling (Cakir
et al., 2009). SIRT1 also modulates the response to NPY,
a neurotransmitter that increases food intake, by activating
FOXO in response to phosphorylation by minibrain/Dyrk1a
kinase (Hong et al., 2012).
SIRT1 is also a critical mediator of the response to ghrelin, a
peptide hormone that stimulates food intake. Ghrelin increases
SIRT1 activity causing p53 deacetylation and AMPK activation,
affecting fatty acid metabolism and feeding behavior (Vela´squez
et al., 2011). Under caloric restriction, SIRT1 increases levels of
the orexin type 2 receptor (Ox2r) in DMH and LH neurons,
increasing responsiveness to ghrelin (Satoh et al., 2010). The
extended lifespan of SIRT1 brain-specific transgenic mice has
also been attributed to upregulation of Ox2r due to deacetylation
of the transcription factor Nk2 homeobox 1 (Satoh et al., 2013).
Other functions attributed to hypothalamic AgRP neurons
including regulation of adaptive immunity, exploratory drive,
and response to cocaine are also altered in mice when SIRT1
is ablated in these cells (Dietrich et al., 2012; Matarese et al.,
2013). Immunologic changes are caused by disinhibition
of POMC neurons that project to the thoracic spinal cord,
increasing sympathetic tone. Deletion of SIRT1 in AgRP neurons
creates a proinflammatory environment, with enhanced effector
T cell activity and decreased regulatory T cell function (Matarese
et al., 2013). AgRP neurons also innervate the ventral tegmental
area (VTA) of the midbrain, and SIRT1 deletion results in higher
levels of dopamine in the forebrain and facilitates long-term
potentiation in a spike-timing-dependent protocol (Dietrich
et al., 2012).Neuron 81, February 5, 2014 ª2014 Elsevier Inc. 473
Figure 3. Sirtuin1 and Hypothalamic
Function
The hypothalamus regulates physiology and
behavior by coordinating neuroendocrine re-
sponses that modulate appetite, temperature,
circadian control, and hormonal release to main-
tain homeostasis (Coppari, 2012). In the ventro-
medial hypothalamic nucleus, SIRT1 increases
energy expenditure and protects against diet-
induced obesity under fed high-fat diets (Ram-
adori et al., 2010, 2011). SIRT1 also regulates
activity and body temperature in the dorsomedial
and lateral hypothalamus (Satoh et al., 2010). In
arcuate nucleus, SIRT1 modulates appetite and
adaptive immunity (Dietrich et al., 2010; Matarese
et al., 2013). In the supraschiasmatic nucleus of
the hypothalamus, SIRT1 levels decrease with
aging, affecting the activity pattern and circadian
period. Overexpressing brain SIRT1 activates the
transcription of BMAL and CLOCK proteins,
enabling animals to be protected from aging-
related changes to the central circadian clock
(Chang and Guarente, 2013).
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behavior and energy expenditure, SIRT1 has also been linked
with circadian control. It was originally shown to regulate circa-
dian rhythm in peripheral tissues, and BMAL1 and PER2 were
identified as SIRT1 targets in the liver (Asher et al., 2008; Naka-
hata et al., 2008). In the supraschiasmatic nucleus of the
hypothalamus, SIRT1 levels decrease with aging, and functional
circadian decline is suppressed by overexpressing SIRT1 in the
brain (Chang and Guarente, 2013). SIRT1 affects BMAL1 tran-
scription by acting cooperatively with PGC1a at RORa-binding
sites. BMAL1 is important for maintaining functional connections
between neurons, synaptic terminals, regulating cerebral redox
homeostasis, and linking circadian clock proteins with neurode-
generation (Musiek et al., 2013). BMAL1 and CLOCK proteins
form heterodimers that activate the transcription of crypto-
chrome (CRY), period (PER), and nicotinamide phosphoribosyl-
transferase (NAMPT), an enzyme that synthesizes NAD+ (Asher
et al., 2008; Nakahata et al., 2008, 2009). Circadian regulation
of NAD+ was recently found to be a major regulator of meta-
bolism and mitochondrial oxidation and metabolism across the
daily cycles of fasting and feeding (Peek et al., 2013).
SIRT1 in Neurodegenerative Disorders
Alzheimer’s Disease
Over 35 million people have dementia worldwide and Alz-
heimer’s disease (AD) is the most common cause of cognitive
impairment (Sosa-Ortiz et al., 2012). Familial AD is an autosomal
dominant neurologic disorder that affects individuals in their 50s
and 60s and is associated with mutations in the genes for amy-
loid precursor protein (APP), presenilin 1 (PS1), or presenilin 2
(PS2). APP is cleaved by b- and g-secretase complexes, leading
to the formation of amyloid-b (ab) peptides that coalesce to form
extracellular plaques. Tau protein also becomes abnormally474 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.aggregated during AD pathogenesis and
forms neurofibrillary tangles within cells.
One of the initial observations raising
the possibility that sirtuins might amelio-rate AD pathology was the finding that resveratrol can reduce
ab-induced toxicity in cell lines (Conte et al., 2003; Jang and
Surh, 2003; Sun et al., 2001) and hippocampal neurons (Han
et al., 2004). Parallel studies in vivo showed that resveratrol could
also reduce plaque formation in transgenic mouse models of AD
(Karuppagounder et al., 2009; Vingtdeux et al., 2010). In order to
link sirtuins more definitively with decrease of amyloid toxicity,
lentiviral infection with SIRT1was performed and decreased ab--
neurotoxicity was observed due to decreased microglial expres-
sion of NF- kB (Chen et al., 2005). A second group identified an
alternate mechanism using cell culture and murine models that
neuronal SIRT1 expression promoted a nonamyloidogenic
APP-processing pathway by decreasing levels of ROCK1 kinase
(Qin et al., 2006). In vivo evidence supporting the idea that SIRT1
overexpression can decrease plaque burden and improve
behavioral phenotypes was performed in the APP/PS1 mouse
model. The retinoic acid receptor b was identified as a
SIRT1 substrate that upregulates alpha-secretase activity by
increasing ADAM10 gene. This results in greater processing of
APP along a nonamyloidogenic pathway (Donmez et al., 2010).
SIRT1 has also been shown to ameliorate tau pathology in the
p25 (Kim et al., 2007) and P301Lmousemodels (Min et al., 2010;
S.W. Min et al., 2012, Soc. Neurosci., conference) affecting
cognitive impairment and mortality. Tau protein is acetylated at
multiple residues early in the disease process and deacetylation
by SIRT1 may allow ubiquitin ligases to target tau for degra-
dation, promoting clearance rather than pathologic intracellular
aggregation of this protein (Cohen et al., 2011; Min et al.,
2010). These mechanisms are schematically represented in
Figure 4.
While these studies support the idea that SIRT1 may influence
both Ab and neurofibrillary tau pathology, more work is needed
to investigate whether SIRT1 activators can be used to treat
Neuron
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onset disorder that is not associated with the same mutations in
APP, PS1, and PS2 that are found in familial AD and are used to
study the disease in mouse and cell-based models. The http://
clinicaltrials.gov registry indicates that there are several ongoing
or recently completed clinical trials testing various formulations
of resveratrol in AD patients. More specific SIRT1 activators,
when they are available, will be invaluable in assessing whether
SIRT1 activating compounds are efficacious in humans.
Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neuro-
logic disease, affecting over 600,000 patients in the United
States (Kowal et al., 2013). Patients develop tremors, rigidity,
and postural instability due to the loss of dopaminergic neurons
in the substantia nigra of the midbrain. Inclusions of a-synuclein
and ubiquitin are a pathologic hallmark of the disease (Blesa
et al., 2012).
A substantial body of literature supports the hypothesis that
SIRT1 is protective in cell culture and animal models of PD
(Albani et al., 2009; Blanchet et al., 2008; Donmez et al., 2012;
Raynes et al., 2012; van Ham et al., 2008; Wu et al., 2011).
Several mechanisms for this effect have been proposed as
SIRT1 deacetylates heat shock factor 1 (HSF1), which increases
transcription of molecular chaperones such as heat shock pro-
tein 70 as is indicated in Figure 4 (Donmez et al., 2012; Raynes
et al., 2012; Westerheide et al., 2009). Another relevant mecha-
nistic pathway may be that SIRT1 can deacetylate PGC1a as
overexpressing PGC1a or resveratrol protect dopaminergic neu-
rons against MPTP-induced cell degeneration (Mudo` et al.,
2012). SIRT1 may also function to regulate autophagy and mi-
tophagy, which may affect a-synuclein toxicity in the context of
PD (Sampaio-Marques et al., 2012; Wu et al., 2011).
Huntington’s Disease
Huntington’s disease (HD) is a rare movement disorder that
causes chorea, loss of motor coordination, cognitive dysfunc-
tion, and dementia. It is an autosomal dominant disease caused
by the expansion of a CAG repeat that codes for a polyglutamine
stretch in the huntingtin protein that affects its aggregation pro-
pensity (La Spada, 2012).
SIRT1 has been evaluated as a potential pharmacologic target
for HD in multiple animal and cell culture systems with mixed
results, depending on the organism, HD model, and endpoints
measured for evaluation. In Drosophila models, SIRT1 inhibition
using either genetic or pharmacologic strategies can suppress
pathogenesis of HD (Pallos et al., 2008). In C. elegans models,
the converse is true and SIRT1 overexpression or resveratrol
treatment is protective (Parker et al., 2005, 2012). In mammalian
systems, studies using pharmacologic agents have not shown
conclusive results with several studies indicating that SIRT1
may be protective (Kumar et al., 2006) and others showing a
modest improvement in motor deficits or peripheral tissues
without a clear improvement in survival (Hathorn et al., 2011;
Ho et al., 2010).
Genetic models of SIRT1 overexpression have yielded greater
clarity with two studies showing that sirtuins can protect against
mutant huntingtin toxicity in three different mouse models of HD
(Jeong et al., 2012; Jiang et al., 2012). One proposedmechanism
is that SIRT1 deacetylates the CREB coactivator TORC1, facili-tating its nuclear localization and BDNF transcriptional activation
via CREB (Jeong et al., 2012). Mutant huntingtin protein was
found to inhibit the enzymatic activity of SIRT1 during HD path-
ogenesis. An alternate explanation for the protective effect of
SIRT1 in HD mice was that this protein might maintain TrkB
signaling and DARPP32 levels as HD progresses. Foxo3a de-
acetylation was another SIRT1 target implicated in promoting
cell survival in the HD models (Jiang et al., 2012). The major
mechanisms for neuroprotection identified in mouse models of
HD are illustrated in Figure 4. Thus, several different molecular
mechanisms may explain the improvements in HD symptoms
in these genetic models, and future experiments will clarify which
targets are critical components of the neuroprotective pheno-
type and whether these findings can be translated into new
therapies for patients with HD.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive
disease that affects motor neurons, compromising muscle
strength and coordination. Over the past few decades, a number
of mutations in a functionally diverse set of genes have been
identified including SOD1 (Rosen et al., 1993), TDP43 (Arai
et al., 2006; Neumann et al., 2006), FUS (Kwiatkowski et al.,
2009), VCP (Johnson et al., 2010), UBQLN2 (Deng et al., 2011),
and C9ORF72 (DeJesus-Hernandez et al., 2011; Renton
et al., 2011). There are many proposed etiologies for ALS
including RNA metabolism, mitochondrial dysfunction, oxidative
damage, protein misfolding, glutamate-mediated excitotoxicity,
and axonal transport defects (Cozzolino et al., 2012).
Several studies using resveratrol and lentiviral injection have
indicated that SIRT1 may be protective in tissue culture (Wang
et al., 2011; Ya´n˜ez et al., 2011) and mouse models of ALS (Han
et al., 2012; Kim et al., 2007). Method of delivery is an important
consideration as two studies have examined the effects of
resveratrol in whole animal SOD mouse models. Intraperitoneal
injection of the compound yielded significant improvements
in morbidity and mortality (Han et al., 2012), whereas dietary
treatment with resveratrol was not found to improve disease
progression (Markert et al., 2010).
The proposed mechanism for SIRT1’s activity in motor neuron
disease parallels its role in mousemodels of PD. SIRT1 has been
shown to deacetylate HSF1, which increases transcription of
molecular chaperones including HSP70 and HSP25 that help
to maintain intracellular protein homeostasis, reducing toxicity
to motor neurons (Han et al., 2012; Raynes et al., 2012; van
Ham et al., 2008; Westerheide et al., 2009). In cell culture models
of ALS, SIRT1 activation may increase mitochondrial biogenesis
through PGC1a (Wang et al., 2011). These mechanisms are illus-
trated in Figure 4. SIRT1 is altered both in the SODmutantmouse
lines (Kim et al., 2007; Lee et al., 2012) as well as in patient sam-
ples (Ko¨rner et al., 2013) and therefore may be promising both as
a disease marker and a therapeutic target for ALS.
Spinal and Bulbar Muscular Atrophy
Spinal and bulbar muscular atrophy (SBMA) is a rare neurologic
disorder that causes muscle weakness and endocrine problems
in males due to its effects on motor and sensory neurons. Also
known as Kennedy’s disease, this disorder is caused by a
CAG trinucleotide expansion in the amino-terminal region of
the androgen receptor (Brinkmann, 2011; La Spada et al.,Neuron 81, February 5, 2014 ª2014 Elsevier Inc. 475
Figure 4. Major Targets and Mechanisms of SIRT1 in Mouse Models of Neurodegenerative Disease
Alzheimer’s disease (highlighted in red). In Alzheimer’s disease, SIRT1 has been shown to promote nonamyloidogenic APP-processing pathway by decreasing
levels of ROCK1 kinase (Qin et al., 2006). SIRT1 also targets the retinoic acid receptor b, which activates ADAM10 to facilitate processing of APP along a
nonamyloidogenic pathway (Donmez et al., 2010). SIRT1 has also been shown to directly deacetylate tau in several tauopathymodels enabling ubiquitin ligases to
promote clearance of this protein (Cohen et al., 2011; Min et al., 2010).
Parkinson’s disease (highlighted in blue). SIRT1 has been shown to deacetylate HSF, which induces transcription of molecular chaperones that promote protein
folding (Donmez et al., 2012; Raynes et al., 2012; Westerheide et al., 2009). In addition to its effects on the heat shock response, SIRT1 may also function to
regulate autophagy and mitophagy, which may affect a-synuclein toxicity in the context of PD (Sampaio-Marques et al., 2012; Wu et al., 2011). There is also
evidence that PGC1a may be a relevant target in mouse models of PD (Mudo` et al., 2012).
Huntington’s disease (highlighted in green). Several different molecular mechanisms account for the protective effect of SIRT1 overexpression against mutant
huntingtin toxicity (Jeong et al., 2012; Jiang et al., 2012). Mutant huntingtin protein was found to inhibit the enzymatic activity of SIRT1 during HD pathogenesis.
One proposed mechanism is that SIRT1 deacetylates TORC1, facilitating BDNF transcription through CREB (Jeong et al., 2012). An alternate explanation for the
protective effect of SIRT1 in HD mice was that this protein might maintain TrkB signaling and DARPP32 levels as HD progresses. Foxo3a deacetylation was
another SIRT1 target implicated in promoting cell survival in the HD models (Jiang et al., 2012).
Amyotrophic lateral sclerosis (highlighted in beige). The proposed mechanism for SIRT1’s activity in Amyotrophic lateral sclerosis parallels one of the pathways
observed in PD. SIRT1 has been shown to deacetylate HSF1, which increases transcription of molecular chaperones including HSP70 and HSP25 that help to
maintain intracellular protein homeostasis, reducing toxicity to motor neurons (Han et al., 2012; Raynes et al., 2012; van Ham et al., 2008; Westerheide
et al., 2009). SIRT1 has also been shown to affect mitochondrial biogenesis in cell culture models of ALS and this may be due to deacetylation of PGC1a (Wang
et al., 2011).
(legend continued on next page)
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ical methods improves the disease phenotype in animal models
(Katsuno et al., 2002, 2003) but has not been shown to improve
symptoms in patients with SBMA (Ferna´ndez-Rhodes et al.,
2011; Katsuno et al., 2010).
Recent work has shown that the androgen receptor (AR) can
be repressed through deacetylation by SIRT1 (Fu et al., 2006).
SIRT1 can also deacetylate the polyglutamine-expanded
androgen receptor in SBMA (Montie et al., 2011). If the androgen
receptor is an SIRT1 substrate in patients, then this finding has
great therapeutic potential because SIRT1 activation may have
fewer side effects relative to androgen withdrawal and other
therapies that have been explored for SBMA treatment.
Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, demyelinating disorder
characterized by intermittent episodes of focal inflammation
and neurologic dysfunction. The disease often leads to gradual
decline and permanent neuronal damage. One of the most es-
tablished models for MS is experimental autoimmune encepha-
litis (EAE), an induced disorder in which T cells react against
myelin antigens and form demyelinating lesions in the CNS of
mice (Olitsky and Yager, 1949).
Several studies show that resveratrol may be protective in
mouse models of MS. In a relapsing-remitting EAE model,
resveratrol was able to reduce neuronal damage but did not
affect inflammation (Shindler et al., 2007, 2010). In chronic EAE
models, resveratrol treatment has also delayed symptom onset
and decreased neuronal loss and paralysis (Fonseca-Kelly
et al., 2012; Singh et al., 2007). In these studies, the mechanism
of action for resveratrol was not established and could be related
to the activity of SIRT1 or other proteins including AMPK or
PGC1a.
A more recent study used genetic overexpression of SIRT1 in
a chronic EAE model and found that clinical symptoms were
improved with less axonal injury and fewer apoptotic cells
observed in the presence of SIRT1 overexpression. This protec-
tive phenotype was associated with increased brain-derived
neurotrophic factor and NAD levels (Nimmagadda et al., 2013).
Other studies examining the effect of SIRT1 in adult neuronal
precursor pools (NPCs) have not shown as clear a picture
regarding the effect of SIRT1 on EAE. In a study examining the
influence of redox state on neural precursor cell (NPC) differen-
tiation, SIRT1 levels increased in glial fibrillary acidic protein
(GFAP)-positive cells near EAE inflammatory lesions. This group
found that SIRT1 increases in NPCs and binds Hes1 under
oxidative conditions, inhibiting Mash1 transcription and driving
NPCs toward astroglial differentiation (Prozorovski et al., 2008).
This pathway may comprise part of the endogenous response
to demyelinating disorders such as MS and is depicted in
Figure 4. A subsequent study showed that deleting SIRT1 in
NPC and neural progenitors prior to induction delayed onset of
paralysis in a chronic EAE model (Rafalski et al., 2013). TakenMultiple sclerosis (highlighted in orange). In experimental autoimmune enceph
protection in whole animal models, has not been completely elucidated. In adult n
inhibitingMash1 transcription and driving NPCs toward astroglial differentiation (P
remyelinate lesions, reduce axonal damage, or decrease astrogliosis. An alterna
explain neuroprotection due to SIRT1 overexpression in EAE (Nimmagadda et atogether, these results suggest that increasing the oligodendro-
cyte population may help remyelinate lesions, reduce axonal
damage, or decrease astrogliosis (Rafalski et al., 2013); how-
ever, the specificity of these genetic models for NPCs may be
less clinically relevant as this small population of cells may be
difficult to target pharmacologically.
Prion Disease
Prion diseases are a group of fatal neurodegenerative conditions
resulting from accumulation of misfolded prion protein that
causes degeneration and apoptosis of neurons. These diseases
are transmitted when infectious, conformationally altered prion
(PrPsc) converts normal cellular prion (PrP) into a pathologic
form that has high b sheet content (Prusiner, 1998). The disease
can be modeled in vitro by inoculating cells with synthetic pep-
tides from the disordered N-terminal domain of the prion protein,
which causes aggregation of endogenous cellular prion. Disease
manifestations are modeled in vivo by direct intracranial inocula-
tion of infectious material or by using transgenic mouse lines
that overexpress mutant prion protein. In mouse strains with
genetically deleted SIRT1, the progagation of prion protein was
delayed (Chen et al., 2008). Other models do not show the
same effect, with genetic and pharmacologic studies in both
nematode and in vitro models of prion toxicity showing protec-
tion against neurodegeneration in the presence of increased
SIRT1 activity (Bizat et al., 2010; Jeong et al., 2013; Seo et al.,
2012). Mechanisitically, SIRT1-mediated deacetylation of p53
and p65 may regulate apoptotic signaling proteins affecting
cell survival (Seo et al., 2012). It has also been shown that
SIRT1may protect against prion disease by inducing autophagy,
which decreases mitochondrial impairment in neurons (Jeong
et al., 2013). Further work will be needed to resolve the differ-
ences in outcomes between these studies and to clarify whether
modulating sirtuin activity is likely to affect the severity or
outcome of prion infection in patients.
SIRT1 in Psychiatric Disorders
A number of genetic association studies have evaluated the rela-
tionship between SIRT1 haplotypes and psychiatric disorders
including schizophrenia, bipolar disorder, anxiety disorder, ma-
jor depressive disorder, and drug-induced psychosis and several
SIRT1 SNPs were overrepresented in patients with depression
and anxiety disorders (Kishi et al., 2010, 2011a, 2011b; Libert
et al., 2011). Another approach investigating a link between sir-
tuins and mood disorders found that levels of SIRT1, SIRT2,
and SIRT6 transcripts decreased in peripheral white blood cells
during depressive and remissive states of patients with major
depression and bipolar disorder (Abe et al., 2011).
In animal models, genetic modulation of SIRT1 levels corre-
lates with anxiety and exploratory drive and is mechanistically
linked with serotonin levels in the brain. SIRT1 deacetylates
NHLH2, a transcription factor that regulates monoamine oxidase
A (MAO-A). This enzyme converts serotonin to 5-hydroxyindole-
acetic acid (5-HIAA). Thus, mice lacking brain SIRT1 havealitis (EAE), the mouse model for multiple sclerosis (MS), the mechanism of
euronal precursor cells (NPCs), SIRT1 binds Hes1 under oxidative conditions,
rozorovski et al., 2008) and increasing the oligodendrocyte populationmay help
te approach has identified increased BDNF and NAMPT as possible targets to
l., 2013).
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nin, whereas mice overexpressing brain SIRT1 are serotonin
deficient. Moreover, behavioral differences in the mice can be
normalized by treatment with anxiolytic or antidepressant med-
ications used in patients such as MAO inhibitors and selective
serotonin reuptake inhibitors (Libert et al., 2011).
SIRT1 may also play an important role in addiction and sub-
stance abuse. Cocaine or morphine administration increases
SIRT1 expression in the nucleus accumbens, a brain region
that regulates motivation and reward (Ferguson et al., 2013;
Renthal et al., 2009). Chronic drug administration increases
binding of activator protein 1 (AP1) sites in the sirtuin promoter
with DFosB, a transcription factor that modulates addiction-
associated behaviors and induces expression of SIRT1 and
SIRT2. Importantly, viral-mediated overexpression of SIRT1 in
this region enhanced the reward response, while knockdown
decreased it (Ferguson et al., 2013). Resveratrol was also found
to have acute effects on cocaine-mediated neurotransmission
by enhancing dopamine neurotransmission (Shuto et al., 2013).
In contrast, in the AgRP neurons of the hypothalamus, knock-
down of SIRT1 enhanced responses to cocaine (Dietrich et al.,
2012). In summary, SIRT1 plays important roles in behavioral
processes by affecting neurotransmitter processing in multiple
brain circuits.
Conclusions and Future Directions
Sirtuins play a critical role in the maintenance of neural systems
and behavior during normal aging. SIRT1 affects neuronal
morphology during development and also is important in main-
taining metabolic and circadian homeostasis during aging. Due
to its hypothalamic effects and peripheral targets, modulation
of SIRT1 activity may be an effective treatment strategy for dia-
betes and obesity. It is also a promising therapeutic target for
a number of neurodegenerative disorders in which it affects
proteostasis and facilitates aggregate clearance.
Modulation of mammalian sirtuins like SIRT1 may thus be a
valuable strategy to slow the trajectory of aging-related degener-
ative changes in the CNS and neurologic disorders. However,
much still needs to be learned about the safety and efficacy pro-
files of sirtuin activators. One exciting new finding in the field of
aging research is that the levels of NAD+, the cosubstrate for
SIRT1–SIRT7, decreases with aging in mice (Mouchiroud et al.,
2013; Ramsey et al., 2008), rats (Braidy et al., 2013), worms
(Mouchiroud et al., 2013), and even humans (Massudi et al.,
2012). This reduction in NAD+ is expected to reduce the activ-
ities of SIRT1–SIRT7 and may thus compromise protection
against neurological decline and neurodegenerative diseases.
Moreover, supplementation of the diet with NAD+ precursors,
such as nicotinamide mononucleotide or nicotinamide riboside,
can restore NAD+ levels and reverse untowardmetabolic pheno-
types in aging mice (Canto´ et al., 2012; Gomes et al., 2013;
Yoshino et al., 2011). The decline in NAD+may be due to chronic
activation of poly-ADP-ribose polymerase by DNA damage,
since PARP inhibition can also restore aging-depleted stores
of NAD+ (Bai et al., 2011; Gomes et al., 2013; Mouchiroud
et al., 2013).
It remains to be seen if this kind of NAD+ depletion occurs in
neurodegenerative diseases. But this is a real possibility, since478 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.these diseases feature a high degree of chronic DNA damage
(Adamec et al., 1999; Ferrante et al., 1997; Robison and Bradley,
1984). One exciting possibility is that sirtuin activators in combi-
nation with NAD+ supplementation will provide a one-two punch
to prevent or even treat neurodegenerative diseases. This possi-
bility would provide a novel broad-based approach, which is
complementary to developing disease-targeted strategies.
ACKNOWLEDGMENTS
We would like to acknowledge the Harvard Neurodiscovery Center Pilot Pro-
jects program (A.Z.H.), NIH, and the Glenn Foundation for Medical Research
for support (L.G.). L.G. consults for GSK, Chronos, Elysiumhealth, and Seg-
terra. We would also like to thank Dr. Masaki Igarashi for helpful comments
on this manuscript.
REFERENCES
Abe, N., Uchida, S., Otsuki, K., Hobara, T., Yamagata, H., Higuchi, F., Shibata,
T., and Watanabe, Y. (2011). Altered sirtuin deacetylase gene expression in
patients with a mood disorder. J. Psychiatr. Res. 45, 1106–1112.
Adamec, E., Vonsattel, J.P., and Nixon, R.A. (1999). DNA strand breaks in
Alzheimer’s disease. Brain Res. 849, 67–77.
Albani, D., Polito, L., Batelli, S., De Mauro, S., Fracasso, C., Martelli, G.,
Colombo, L., Manzoni, C., Salmona, M., Caccia, S., et al. (2009). The SIRT1
activator resveratrol protects SK-N-BE cells from oxidative stress and against
toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide.
J. Neurochem. 110, 1445–1456.
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D.,
Tsuchiya, K., Yoshida, M., Hashizume, Y., and Oda, T. (2006). TDP-43 is a
component of ubiquitin-positive tau-negative inclusions in frontotemporal
lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys.
Res. Commun. 351, 602–611.
Ardestani, P.M., and Liang, F. (2012). Sub-cellular localization, expression and
functions of Sirt6 during the cell cycle in HeLa cells. Nucleus 3, 442–451.
Asher, G., Gatfield, D., Stratmann, M., Reinke, H., Dibner, C., Kreppel, F., Mos-
toslavsky, R., Alt, F.W., and Schibler, U. (2008). SIRT1 regulates circadian
clock gene expression through PER2 deacetylation. Cell 134, 317–328.
Bai, P., Canto´, C., Oudart, H., Brunya´nszki, A., Cen, Y., Thomas, C., Yama-
moto, H., Huber, A., Kiss, B., Houtkooper, R.H., et al. (2011). PARP-1 inhibition
increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13,
461–468.
Barber, M.F., Michishita-Kioi, E., Xi, Y., Tasselli, L., Kioi, M., Moqtaderi, Z.,
Tennen, R.I., Paredes, S., Young, N.L., Chen, K., et al. (2012). SIRT7 links
H3K18 deacetylation to maintenance of oncogenic transformation. Nature
487, 114–118.
Bellet, M.M., Orozco-Solis, R., Sahar, S., Eckel-Mahan, K., and Sassone-
Corsi, P. (2011). The time of metabolism: NAD+, SIRT1, and the circadian
clock. Cold Spring Harb. Symp. Quant. Biol. 76, 31–38.
Bellet, M.M., Nakahata, Y., Boudjelal, M., Watts, E., Mossakowska, D.E.,
Edwards, K.A., Cervantes, M., Astarita, G., Loh, C., Ellis, J.L., et al. (2013).
Pharmacological modulation of circadian rhythms by synthetic activators of
the deacetylase SIRT1. Proc. Natl. Acad. Sci. USA 110, 3333–3338.
Bizat, N., Peyrin, J.M., Haı¨k, S., Cochois, V., Beaudry, P., Laplanche, J.L., and
Ne´ri, C. (2010). Neuron dysfunction is induced by prion protein with an inser-
tional mutation via a Fyn kinase and reversed by sirtuin activation in Caeno-
rhabditis elegans. J. Neurosci. 30, 5394–5403.
Blanchet, J., Longpre´, F., Bureau, G., Morissette, M., DiPaolo, T., Bronchti, G.,
and Martinoli, M.G. (2008). Resveratrol, a red wine polyphenol, protects
dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol.
Biol. Psychiatry 32, 1243–1250.
Blesa, J., Phani, S., Jackson-Lewis, V., and Przedborski, S. (2012). Classic and
new animal models of Parkinson’s disease. J. Biomed. Biotechnol. 2012,
845618.
Neuron
ReviewBraidy, N., Poljak, A., Grant, R., Jayasena, T., Mansour, H., Chan-Ling, T., Guil-
lemin, G.J., Smythe, G., and Sachdev, P. (2013). Mapping NAD metabolism in
the brain of ageing Wistar rats: potential targets for influencing brain senes-
cence. Biogerontology. Published online December 17, 2013. http://dx.doi.
org/10.1007/s10522-013-9489-5.
Brinkmann, A.O. (2011). Molecular mechanisms of androgen action–a histori-
cal perspective. Methods Mol. Biol. 776, 3–24.
Brunet, A., Sweeney, L.B., Sturgill, J.F., Chua, K.F., Greer, P.L., Lin, Y., Tran,
H., Ross, S.E., Mostoslavsky, R., Cohen, H.Y., et al. (2004). Stress-dependent
regulation of FOXO transcription factors by the SIRT1 deacetylase. Science
303, 2011–2015.
Byles, V., Chmilewski, L.K., Wang, J., Zhu, L., Forman, L.W., Faller, D.V., and
Dai, Y. (2010). Aberrant cytoplasm localization and protein stability of SIRT1 is
regulated by PI3K/IGF-1R signaling in human cancer cells. Int. J. Biol. Sci. 6,
599–612.
Cakir, I., Perello, M., Lansari, O., Messier, N.J., Vaslet, C.A., and Nillni, E.A.
(2009). Hypothalamic Sirt1 regulates food intake in a rodent model system.
PLoS ONE 4, e8322.
Canto´, C., Houtkooper, R.H., Pirinen, E., Youn, D.Y., Oosterveer, M.H., Cen,
Y., Fernandez-Marcos, P.J., Yamamoto, H., Andreux, P.A., Cettour-Rose,
P., et al. (2012). The NAD(+) precursor nicotinamide riboside enhances
oxidative metabolism and protects against high-fat diet-induced obesity.
Cell Metab. 15, 838–847.
Chang, H.C., and Guarente, L. (2013). SIRT1 mediates central circadian con-
trol in the SCN by a mechanism that decays with aging. Cell 153, 1448–1460.
Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.F., Kwon, H., Yi, S., Mucke, L.,
and Gan, L. (2005). SIRT1 protects against microglia-dependent amyloid-beta
toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem. 280, 40364–
40374.
Chen, D., Steele, A.D., Hutter, G., Bruno, J., Govindarajan, A., Easlon, E., Lin,
S.J., Aguzzi, A., Lindquist, S., and Guarente, L. (2008). The role of calorie
restriction and SIRT1 in prion-mediated neurodegeneration. Exp. Gerontol.
43, 1086–1093.
Chopra, V., Quinti, L., Kim, J., Vollor, L., Narayanan, K.L., Edgerly, C., Cipic-
chio, P.M., Lauver, M.A., Choi, S.H., Silverman, R.B., et al. (2012). The sirtuin
2 inhibitor AK-7 is neuroprotective in Huntington’s diseasemousemodels. Cell
Rep 2, 1492–1497.
Codocedo, J.F., Allard, C., Godoy, J.A., Varela-Nallar, L., and Inestrosa, N.C.
(2012). SIRT1 regulates dendritic development in hippocampal neurons. PLoS
One 7, e47073.
Cohen, D.E., Supinski, A.M., Bonkowski, M.S., Donmez, G., and Guarente,
L.P. (2009). Neuronal SIRT1 regulates endocrine and behavioral responses
to calorie restriction. Genes Dev. 23, 2812–2817.
Cohen, T.J., Guo, J.L., Hurtado, D.E., Kwong, L.K., Mills, I.P., Trojanowski,
J.Q., and Lee, V.M. (2011). The acetylation of tau inhibits its function and pro-
motes pathological tau aggregation. Nat Commun 2, 252.
Conte, A., Pellegrini, S., and Tagliazucchi, D. (2003). Synergistic protection of
PC12 cells from beta-amyloid toxicity by resveratrol and catechin. Brain Res.
Bull. 62, 29–38.
Coppari, R. (2012). Metabolic actions of hypothalamic SIRT1. Trends Endocri-
nol. Metab. 23, 179–185.
Cozzolino, M., Pesaresi, M.G., Gerbino, V., Grosskreutz, J., and Carrı`, M.T.
(2012). Amyotrophic lateral sclerosis: new insights into underlying molecular
mechanisms and opportunities for therapeutic intervention. Antioxid. Redox
Signal. 17, 1277–1330.
DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M.,
Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J., et al.
(2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of
C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245–256.
Deng, H.X., Chen, W., Hong, S.T., Boycott, K.M., Gorrie, G.H., Siddique, N.,
Yang, Y., Fecto, F., Shi, Y., Zhai, H., et al. (2011). Mutations in UBQLN2 cause
dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature
477, 211–215.Dietrich, M.O., Antunes, C., Geliang, G., Liu, Z.W., Borok, E., Nie, Y., Xu, A.W.,
Souza, D.O., Gao, Q., Diano, S., et al. (2010). Agrp neurons mediate Sirt1’s
action on the melanocortin system and energy balance: roles for Sirt1 in
neuronal firing and synaptic plasticity. J. Neurosci. 30, 11815–11825.
Dietrich, M.O., Bober, J., Ferreira, J.G., Tellez, L.A., Mineur, Y.S., Souza, D.O.,
Gao, X.B., Picciotto, M.R., Arau´jo, I., Liu, Z.W., and Horvath, T.L. (2012). AgRP
neurons regulate development of dopamine neuronal plasticity and nonfood-
associated behaviors. Nat. Neurosci. 15, 1108–1110.
Dokmanovic, M., Clarke, C., and Marks, P.A. (2007). Histone deacetylase
inhibitors: overview and perspectives. Mol. Cancer Res. 5, 981–989.
Donmez, G., Wang, D., Cohen, D.E., and Guarente, L. (2010). SIRT1 sup-
presses beta-amyloid production by activating the alpha-secretase gene
ADAM10. Cell 142, 320–332.
Donmez, G., Arun, A., Chung, C.Y., McLean, P.J., Lindquist, S., and Guarente,
L. (2012). SIRT1 protects against a-synuclein aggregation by activating molec-
ular chaperones. J. Neurosci. 32, 124–132.
Du, J., Zhou, Y., Su, X., Yu, J.J., Khan, S., Jiang, H., Kim, J., Woo, J., Kim, J.H.,
Choi, B.H., et al. (2011). Sirt5 is a NAD-dependent protein lysine demalonylase
and desuccinylase. Science 334, 806–809.
Eskandarian, H.A., Impens, F., Nahori, M.A., Soubigou, G., Coppe´e, J.Y., Cos-
sart, P., and Hamon, M.A. (2013). A role for SIRT2-dependent histone H3K18
deacetylation in bacterial infection. Science 341, 1238858.
Ferguson, D., Koo, J.W., Feng, J., Heller, E., Rabkin, J., Heshmati, M., Renthal,
W., Neve, R., Liu, X., Shao, N., et al. (2013). Essential role of SIRT1 signaling in
the nucleus accumbens in cocaine and morphine action. J. Neurosci. 33,
16088–16098.
Ferna´ndez-Rhodes, L.E., Kokkinis, A.D., White, M.J., Watts, C.A., Auh, S., Jef-
fries, N.O., Shrader, J.A., Lehky, T.J., Li, L., Ryder, J.E., et al. (2011). Efficacy
and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a
randomised placebo-controlled trial. Lancet Neurol. 10, 140–147.
Ferrante, R.J., Browne, S.E., Shinobu, L.A., Bowling, A.C., Baik, M.J.,
MacGarvey, U., Kowall, N.W., Brown, R.H., Jr., and Beal, M.F. (1997). Evi-
dence of increased oxidative damage in both sporadic and familial amyotro-
phic lateral sclerosis. J. Neurochem. 69, 2064–2074.
Fonseca-Kelly, Z., Nassrallah, M., Uribe, J., Khan, R.S., Dine, K., Dutt, M., and
Shindler, K.S. (2012). Resveratrol neuroprotection in a chronic mousemodel of
multiple sclerosis. Front. Neurol. 3, 84.
Ford, E., Voit, R., Liszt, G., Magin, C., Grummt, I., and Guarente, L. (2006).
Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcrip-
tion. Genes Dev. 20, 1075–1080.
Frye, R.A. (1999). Characterization of five human cDNAs with homology to the
yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have
protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun.
260, 273–279.
Frye, R.A. (2000). Phylogenetic classification of prokaryotic and eukaryotic
Sir2-like proteins. Biochem. Biophys. Res. Commun. 273, 793–798.
Fu, M., Liu, M., Sauve, A.A., Jiao, X., Zhang, X., Wu, X., Powell, M.J., Yang, T.,
Gu, W., Avantaggiati, M.L., et al. (2006). Hormonal control of androgen recep-
tor function through SIRT1. Mol. Cell. Biol. 26, 8122–8135.
Gao, J., Wang,W.Y.,Mao, Y.W., Gra¨ff, J., Guan, J.S., Pan, L., Mak, G., Kim, D.,
Su, S.C., and Tsai, L.H. (2010). A novel pathway regulates memory and
plasticity via SIRT1 and miR-134. Nature 466, 1105–1109.
Gomes, A.P., Price, N.L., Ling, A.J., Moslehi, J.J., Montgomery, M.K., Rajman,
L., White, J.P., Teodoro, J.S., Wrann, C.D., Hubbard, B.P., et al. (2013).
Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mito-
chondrial communication during aging. Cell 155, 1624–1638.
Gregoretti, I.V., Lee, Y.M., and Goodson, H.V. (2004). Molecular evolution
of the histone deacetylase family: functional implications of phylogenetic
analysis. J. Mol. Biol. 338, 17–31.
Guarente, L. (2013). Calorie restriction and sirtuins revisited. Genes Dev. 27,
2072–2085.Neuron 81, February 5, 2014 ª2014 Elsevier Inc. 479
Neuron
ReviewGuo, W., Qian, L., Zhang, J., Zhang, W., Morrison, A., Hayes, P., Wilson, S.,
Chen, T., and Zhao, J. (2011). Sirt1 overexpression in neurons promotes neu-
rite outgrowth and cell survival through inhibition of the mTOR signaling.
J. Neurosci. Res. 89, 1723–1736.
Haigis, M.C., Mostoslavsky, R., Haigis, K.M., Fahie, K., Christodoulou, D.C.,
Murphy, A.J., Valenzuela, D.M., Yancopoulos, G.D., Karow, M., Blander, G.,
et al. (2006). SIRT4 inhibits glutamate dehydrogenase and opposes the effects
of calorie restriction in pancreatic beta cells. Cell 126, 941–954.
Han, Y.S., Zheng, W.H., Bastianetto, S., Chabot, J.G., and Quirion, R. (2004).
Neuroprotective effects of resveratrol against beta-amyloid-induced neuro-
toxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J.
Pharmacol. 141, 997–1005.
Han, S., Choi, J.R., Soon Shin, K., and Kang, S.J. (2012). Resveratrol upregu-
lated heat shock proteins and extended the survival of G93A-SOD1 mice.
Brain Res. 1483, 112–117.
Hathorn, T., Snyder-Keller, A., and Messer, A. (2011). Nicotinamide improves
motor deficits and upregulates PGC-1a andBDNF gene expression in amouse
model of Huntington’s disease. Neurobiol. Dis. 41, 43–50.
Hirschey, M.D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard,
D.B., Grueter, C.A., Harris, C., Biddinger, S., Ilkayeva, O.R., et al. (2010).
SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme de-
acetylation. Nature 464, 121–125.
Hisahara, S., Chiba, S., Matsumoto, H., Tanno, M., Yagi, H., Shimohama, S.,
Sato, M., and Horio, Y. (2008). Histone deacetylase SIRT1modulates neuronal
differentiation by its nuclear translocation. Proc. Natl. Acad. Sci. USA 105,
15599–15604.
Ho, D.J., Calingasan, N.Y., Wille, E., Dumont, M., and Beal, M.F. (2010).
Resveratrol protects against peripheral deficits in a mouse model of Hunting-
ton’s disease. Exp. Neurol. 225, 74–84.
Hong, S.H., Lee, K.S., Kwak, S.J., Kim, A.K., Bai, H., Jung, M.S., Kwon, O.Y.,
Song, W.J., Tatar, M., and Yu, K. (2012). Minibrain/Dyrk1a regulates food
intake through the Sir2-FOXO-sNPF/NPY pathway in Drosophila and mam-
mals. PLoS Genet. 8, e1002857.
Hubbard, B.P., Gomes, A.P., Dai, H., Li, J., Case, A.W., Considine, T., Riera,
T.V., Lee, J.E., e, S.Y., Lamming, D.W., et al. (2013). Evidence for a common
mechanism of SIRT1 regulation by allosteric activators. Science 339, 1216–
1219.
Imaoka, N., Hiratsuka, M., Osaki, M., Kamitani, H., Kambe, A., Fukuoka, J.,
Kurimoto, M., Nagai, S., Okada, F., Watanabe, T., et al. (2012). Prognostic
significance of sirtuin 2 protein nuclear localization in glioma: an immunohisto-
chemical study. Oncol. Rep. 28, 923–930.
Imai, S., Armstrong, C.M., Kaeberlein, M., and Guarente, L. (2000). Transcrip-
tional silencing and longevity protein Sir2 is an NAD-dependent histone deace-
tylase. Nature 403, 795–800.
Jang, J.H., and Surh, Y.J. (2003). Protective effect of resveratrol on beta-
amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 34,
1100–1110.
Jeong, H., Cohen, D.E., Cui, L., Supinski, A., Savas, J.N., Mazzulli, J.R., Yates,
J.R., 3rd, Bordone, L., Guarente, L., and Krainc, D. (2012). Sirt1 mediates neu-
roprotection from mutant huntingtin by activation of the TORC1 and CREB
transcriptional pathway. Nat. Med. 18, 159–165.
Jeong, J.K., Moon, M.H., Lee, Y.J., Seol, J.W., and Park, S.Y. (2013). Auto-
phagy induced by the class III histone deacetylase Sirt1 prevents prion peptide
neurotoxicity. Neurobiol. Aging 34, 146–156.
Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim,
R., Ge, E., Mostoslavsky, R., et al. (2013). SIRT6 regulates TNF-alpha secretion
through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110–113.
Jiang,M.,Wang, J., Fu, J., Du, L., Jeong, H.,West, T., Xiang, L., Peng, Q., Hou,
Z., Cai, H., et al. (2012). Neuroprotective role of Sirt1 in mammalian models of
Huntington’s disease through activation of multiple Sirt1 targets. Nat. Med. 18,
153–158.
Jin, Q., Yan, T., Ge, X., Sun, C., Shi, X., and Zhai, Q. (2007). Cytoplasm-local-
ized SIRT1 enhances apoptosis. J. Cell. Physiol. 213, 88–97.480 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.Johnson, J.O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V.M.,
Trojanowski, J.Q., Gibbs, J.R., Brunetti, M., Gronka, S., Wuu, J., et al.;
ITALSGEN Consortium (2010). Exome sequencing reveals VCP mutations as
a cause of familial ALS. Neuron 68, 857–864.
Kaeberlein, M., McVey, M., and Guarente, L. (1999). The SIR2/3/4 complex
and SIR2 alone promote longevity in Saccharomyces cerevisiae by two
different mechanisms. Genes Dev. 13, 2570–2580.
Karuppagounder, S.S., Pinto, J.T., Xu, H., Chen, H.L., Beal, M.F., and Gibson,
G.E. (2009). Dietary supplementation with resveratrol reduces plaque pathol-
ogy in a transgenic model of Alzheimer’s disease. Neurochem. Int. 54,
111–118.
Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C.,
Kobayashi, Y., Doyu, M., and Sobue, G. (2002). Testosterone reduction pre-
vents phenotypic expression in a transgenicmousemodel of spinal and bulbar
muscular atrophy. Neuron 35, 843–854.
Katsuno, M., Adachi, H., Doyu, M., Minamiyama, M., Sang, C., Kobayashi, Y.,
Inukai, A., and Sobue, G. (2003). Leuprorelin rescues polyglutamine-depen-
dent phenotypes in a transgenic mouse model of spinal and bulbar muscular
atrophy. Nat. Med. 9, 768–773.
Katsuno, M., Banno, H., Suzuki, K., Takeuchi, Y., Kawashima, M., Yabe, I.,
Sasaki, H., Aoki, M., Morita, M., Nakano, I., et al.; Japan SBMA Interventional
Trial for TAP-144-SR (JASMITT) study group (2010). Efficacy and safety of
leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT
study): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet Neurol. 9, 875–884.
Kim, S., Benguria, A., Lai, C.Y., and Jazwinski, S.M. (1999). Modulation of life-
span by histone deacetylase genes in Saccharomyces cerevisiae. Mol. Biol.
Cell 10, 3125–3136.
Kim, D., Nguyen, M.D., Dobbin, M.M., Fischer, A., Sananbenesi, F., Rodgers,
J.T., Delalle, I., Baur, J.A., Sui, G., Armour, S.M., et al. (2007). SIRT1 deacety-
lase protects against neurodegeneration in models for Alzheimer’s disease
and amyotrophic lateral sclerosis. EMBO J. 26, 3169–3179.
Kishi, T., Yoshimura, R., Kitajima, T., Okochi, T., Okumura, T., Tsunoka, T.,
Yamanouchi, Y., Kinoshita, Y., Kawashima, K., Fukuo, Y., et al. (2010).
SIRT1 gene is associated with major depressive disorder in the Japanese pop-
ulation. J. Affect. Disord. 126, 167–173.
Kishi, T., Fukuo, Y., Kitajima, T., Okochi, T., Yamanouchi, Y., Kinoshita, Y.,
Kawashima, K., Inada, T., Kunugi, H., Kato, T., et al. (2011a). SIRT1 gene,
schizophrenia and bipolar disorder in the Japanese population: an association
study. Genes Brain Behav. 10, 257–263.
Kishi, T., Fukuo, Y., Okochi, T., Kitajima, T., Ujike, H., Inada, T., Yamada, M.,
Uchimura, N., Sora, I., Iyo, M., et al. (2011b). No significant association be-
tween SIRT1 gene andmethamphetamine-induced psychosis in the Japanese
population. Hum. Psychopharmacol. 26, 445–450.
Klar, A.J., Fogel, S., and Macleod, K. (1979). MAR1-a Regulator of the HMa
and HMalpha Loci in SACCHAROMYCES CEREVISIAE. Genetics 93, 37–50.
Ko¨rner, S., Bo¨selt, S., Thau, N., Rath, K.J., Dengler, R., and Petri, S. (2013). Dif-
ferential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) post-
mortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS?
Neurodegener. Dis. 11, 141–152.
Kowal, S.L., Dall, T.M., Chakrabarti, R., Storm, M.V., and Jain, A. (2013). The
current and projected economic burden of Parkinson’s disease in the United
States. Mov. Disord. 28, 311–318.
Kumar, P., Padi, S.S., Naidu, P.S., and Kumar, A. (2006). Effect of resveratrol
on 3-nitropropionic acid-induced biochemical and behavioural changes:
possible neuroprotective mechanisms. Behav. Pharmacol. 17, 485–492.
Kwiatkowski, T.J., Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg,
C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T., et al. (2009).
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic
lateral sclerosis. Science 323, 1205–1208.
La Spada, A.R. (2012). Finding a sirtuin truth in Huntington’s disease. Nat.
Med. 18, 24–26.
Neuron
ReviewLa Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E., and Fischbeck,
K.H. (1991). Androgen receptor gene mutations in X-linked spinal and bulbar
muscular atrophy. Nature 352, 77–79.
Landry, J., Sutton, A., Tafrov, S.T., Heller, R.C., Stebbins, J., Pillus, L., and
Sternglanz, R. (2000). The silencing protein SIR2 and its homologs are NAD-
dependent protein deacetylases. Proc. Natl. Acad. Sci. USA 97, 5807–5811.
Lee, J.C., Shin, J.H., Park, B.W., Kim, G.S., Kim, J.C., Kang, K.S., and Cha, C.I.
(2012). Region-specific changes in the immunoreactivity of SIRT1 expression
in the central nervous system of SOD1(G93A) transgenic mice as an in vivo
model of amyotrophic lateral sclerosis. Brain Res. 1433, 20–28.
Li, X.H., Chen, C., Tu, Y., Sun, H.T., Zhao, M.L., Cheng, S.X., Qu, Y., and
Zhang, S. (2013). Sirt1 promotes axonogenesis by deacetylation of Akt and
inactivation of GSK3. Mol. Neurobiol. 48, 490–499.
Libert, S., Pointer, K., Bell, E.L., Das, A., Cohen, D.E., Asara, J.M., Kapur, K.,
Bergmann, S., Preisig, M., Otowa, T., et al. (2011). SIRT1 activates MAO-A
in the brain to mediate anxiety and exploratory drive. Cell 147, 1459–1472.
Liszt, G., Ford, E., Kurtev, M., and Guarente, L. (2005). Mouse Sir2 homolog
SIRT6 is a nuclear ADP-ribosyltransferase. J. Biol. Chem. 280, 21313–21320.
Liu, C.M., Wang, R.Y., Saijilafu, Jiao, Z.X., Zhang, B.Y., and Zhou, F.Q. (2013).
MicroRNA-138 and SIRT1 form a mutual negative feedback loop to regulate
mammalian axon regeneration. Genes Dev. 27, 1473–1483.
Markert, C.D., Kim, E., Gifondorwa, D.J., Childers, M.K., and Milligan, C.E.
(2010). A single-dose resveratrol treatment in a mouse model of amyotrophic
lateral sclerosis. J. Med. Food 13, 1081–1085.
Massudi, H., Grant, R., Braidy, N., Guest, J., Farnsworth, B., and Guillemin,
G.J. (2012). Age-associated changes in oxidative stress and NAD+ meta-
bolism in human tissue. PLoS ONE 7, e42357.
Matarese, G., Procaccini, C., Menale, C., Kim, J.G., Kim, J.D., Diano, S.,
Diano, N., De Rosa, V., Dietrich, M.O., and Horvath, T.L. (2013). Hunger-
promoting hypothalamic neurons modulate effector and regulatory T-cell
responses. Proc. Natl. Acad. Sci. USA 110, 6193–6198.
Merry, D.E. (2012). Attacking the flank: targeting new pathways in SBMA. Nat.
Med. 18, 1461–1463.
Micha´n, S., Li, Y., Chou, M.M., Parrella, E., Ge, H., Long, J.M., Allard, J.S.,
Lewis, K., Miller, M., Xu, W., et al. (2010). SIRT1 is essential for normal cogni-
tive function and synaptic plasticity. J. Neurosci. 30, 9695–9707.
Michishita, E., McCord, R.A., Berber, E., Kioi, M., Padilla-Nash, H., Damian,
M., Cheung, P., Kusumoto, R., Kawahara, T.L., Barrett, J.C., et al. (2008).
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chro-
matin. Nature 452, 492–496.
Michishita, E., Park, J.Y., Burneskis, J.M., Barrett, J.C., and Horikawa, I.
(2005). Evolutionarily conserved and nonconserved cellular localizations and
functions of human SIRT proteins. Mol. Biol. Cell 16, 4623–4635.
Min, S.W., Cho, S.H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W.W.,
Huang, E.J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010). Acetylation of
tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966.
Montie, H.L., Pestell, R.G., and Merry, D.E. (2011). SIRT1 modulates aggrega-
tion and toxicity through deacetylation of the androgen receptor in cell models
of SBMA. J. Neurosci. 31, 17425–17436.
Mostoslavsky, R., Chua, K.F., Lombard, D.B., Pang, W.W., Fischer, M.R., Gel-
lon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M.M., et al. (2006).
Genomic instability and aging-like phenotype in the absence of mammalian
SIRT6. Cell 124, 315–329.
Mouchiroud, L., Houtkooper, R.H., Moullan, N., Katsyuba, E., Ryu, D., Canto´,
C., Mottis, A., Jo, Y.S., Viswanathan, M., Schoonjans, K., et al. (2013). The
NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochon-
drial UPR and FOXO Signaling. Cell 154, 430–441.
Mudo`, G., Ma¨kela¨, J., Di Liberto, V., Tselykh, T.V., Olivieri, M., Piepponen, P.,
Eriksson, O., Ma¨lkia¨, A., Bonomo, A., Kairisalo, M., et al. (2012). Transgenic
expression and activation of PGC-1a protect dopaminergic neurons in the
MPTPmousemodel of Parkinson’s disease. Cell. Mol. Life Sci. 69, 1153–1165.Musiek, E.S., Lim, M.M., Yang, G., Bauer, A.Q., Qi, L., Lee, Y., Roh, J.H.,
Ortiz-Gonzalez, X., Dearborn, J.T., Culver, J.P., et al. (2013). Circadian clock
proteins regulate neuronal redox homeostasis and neurodegeneration.
J. Clin. Invest. 123, 5389–5400.
Nakagawa, T., Lomb, D.J., Haigis, M.C., and Guarente, L. (2009). SIRT5
Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle.
Cell 137, 560–570.
Nakahata, Y., Kaluzova, M., Grimaldi, B., Sahar, S., Hirayama, J., Chen, D.,
Guarente, L.P., and Sassone-Corsi, P. (2008). The NAD+-dependent deacety-
lase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian
control. Cell 134, 329–340.
Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M., and Sassone-Corsi, P.
(2009). Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1.
Science 324, 654–657.
Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C.,
Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M., et al. (2006).
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic
lateral sclerosis. Science 314, 130–133.
Nimmagadda, V.K., Bever, C.T., Vattikunta, N.R., Talat, S., Ahmad, V., Nagalla,
N.K., Trisler, D., Judge, S.I., Royal, W., 3rd, Chandrasekaran, K., et al. (2013).
Overexpression of SIRT1 protein in neurons protects against experimental
autoimmune encephalomyelitis through activation of multiple SIRT1 targets.
J. Immunol. 190, 4595–4607.
Noh, S.J., Baek, H.A., Park, H.S., Jang, K.Y., Moon, W.S., Kang, M.J., Lee,
D.G., Kim, M.H., Lee, J.H., and Chung, M.J. (2013). Expression of SIRT1 and
cortactin is associated with progression of non-small cell lung cancer. Pathol.
Res. Pract. 209, 365–370.
North, B.J., and Verdin, E. (2004). Sirtuins: Sir2-related NAD-dependent pro-
tein deacetylases. Genome Biol. 5, 224.
North, B.J., and Verdin, E. (2007). Interphase nucleo-cytoplasmic shuttling and
localization of SIRT2 during mitosis. PloS One 2, e784.
North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M., and Verdin, E. (2003). The
human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol.
Cell 11, 437–444.
Olitsky, P.K., and Yager, R.H. (1949). Experimental disseminated encephalo-
myelitis in white mice. J. Exp. Med. 90, 213–224.
Onyango, P., Celic, I., McCaffery, J.M., Boeke, J.D., and Feinberg, A.P. (2002).
SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized
to mitochondria. Proc. Natl. Acad. Sci. USA 99, 13653–13658.
Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E.,
Amore, A.M., Volk, C.B., Maxwell, M.M., Rochet, J.C., McLean, P.J., et al.
(2007). Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models
of Parkinson’s disease. Science 317, 516–519.
Pallos, J., Bodai, L., Lukacsovich, T., Purcell, J.M., Steffan, J.S., Thompson,
L.M., and Marsh, J.L. (2008). Inhibition of specific HDACs and sirtuins sup-
presses pathogenesis in a Drosophila model of Huntington’s disease. Hum.
Mol. Genet. 17, 3767–3775.
Park, S.J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H.,
Rehmann, H., Taussig, R., Brown, A.L., et al. (2012). Resveratrol ameliorates
aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.
Cell 148, 421–433.
Parker, J.A., Arango,M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire,
H., and Ne´ri, C. (2005). Resveratrol rescues mutant polyglutamine cytotoxicity
in nematode and mammalian neurons. Nat. Genet. 37, 349–350.
Parker, J.A., Vazquez-Manrique, R.P., Tourette, C., Farina, F., Offner, N.,
Mukhopadhyay, A., Orfila, A.M., Darbois, A., Menet, S., Tissenbaum, H.A.,
and Neri, C. (2012). Integration of b-catenin, sirtuin, and FOXO signaling pro-
tects from mutant huntingtin toxicity. J. Neurosci. 32, 12630–12640.
Peek, C.B., Affinati, A.H., Ramsey, K.M., Kuo, H.Y., Yu, W., Sena, L.A.,
Ilkayeva, O., Marcheva, B., Kobayashi, Y., Omura, C., et al. (2013). Circadian
clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science
342, 1243417.Neuron 81, February 5, 2014 ª2014 Elsevier Inc. 481
Neuron
ReviewPeng, C., Lu, Z., Xie, Z., Cheng, Z., Chen, Y., Tan, M., Luo, H., Zhang, Y., He,
W., Yang, K., et al. (2011). The first identification of lysine malonylation
substrates and its regulatory enzyme. Mol. Cell. Proteomics 10, 012658.
Prozorovski, T., Schulze-Topphoff, U., Glumm, R., Baumgart, J., Schro¨ter, F.,
Ninnemann, O., Siegert, E., Bendix, I., Bru¨stle, O., Nitsch, R., et al. (2008). Sirt1
contributes critically to the redox-dependent fate of neural progenitors. Nat.
Cell Biol. 10, 385–394.
Prusiner, S.B. (1998). Prions. Proc. Natl. Acad. Sci. USA 95, 13363–13383.
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan,
M., MacGrogan, D., Rodgers, J.T., et al. (2006). Neuronal SIRT1 activation as a
novel mechanism underlying the prevention of Alzheimer disease amyloid
neuropathology by calorie restriction. J. Biol. Chem. 281, 21745–21754.
Rafalski, V.A., Ho, P.P., Brett, J.O., Ucar, D., Dugas, J.C., Pollina, E.A., Chow,
L.M., Ibrahim, A., Baker, S.J., Barres, B.A., et al. (2013). Expansion of oligo-
dendrocyte progenitor cells following SIRT1 inactivation in the adult brain.
Nat. Cell Biol. 15, 614–624.
Ramadori, G., Lee, C.E., Bookout, A.L., Lee, S., Williams, K.W., Anderson, J.,
Elmquist, J.K., and Coppari, R. (2008). Brain SIRT1: anatomical distribution
and regulation by energy availability. J. Neurosci. 28, 9989–9996.
Ramadori, G., Fujikawa, T., Fukuda, M., Anderson, J., Morgan, D.A., Mosto-
slavsky, R., Stuart, R.C., Perello, M., Vianna, C.R., Nillni, E.A., et al. (2010).
SIRT1 deacetylase in POMC neurons is required for homeostatic defenses
against diet-induced obesity. Cell Metab. 12, 78–87.
Ramadori, G., Fujikawa, T., Anderson, J., Berglund, E.D., Frazao, R., Micha´n,
S., Vianna, C.R., Sinclair, D.A., Elias, C.F., and Coppari, R. (2011). SIRT1 de-
acetylase in SF1 neurons protects against metabolic imbalance. Cell Metab.
14, 301–312.
Ramsey, K.M., Mills, K.F., Satoh, A., and Imai, S. (2008). Age-associated loss
of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta
cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7, 78–88.
Raynes, R., Leckey, B.D., Jr., Nguyen, K., and Westerheide, S.D. (2012). Heat
shock and caloric restriction have a synergistic effect on the heat shock
response in a sir2.1-dependent manner in Caenorhabditis elegans. J. Biol.
Chem. 287, 29045–29053.
Renthal, W., Kumar, A., Xiao, G., Wilkinson, M., Covington, H.E., 3rd, Maze, I.,
Sikder, D., Robison, A.J., LaPlant, Q., Dietz, D.M., et al. (2009). Genome-wide
analysis of chromatin regulation by cocaine reveals a role for sirtuins. Neuron
62, 335–348.
Renton, A.E., Majounie, E., Waite, A., Simo´n-Sa´nchez, J., Rollinson, S., Gibbs,
J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L., et al.;
ITALSGEN Consortium (2011). A hexanucleotide repeat expansion in
C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72,
257–268.
Rine, J., Strathern, J.N., Hicks, J.B., and Herskowitz, I. (1979). A suppressor of
mating-type locus mutations in Saccharomyces cerevisiae: evidence for and
identification of cryptic mating-type loci. Genetics 93, 877–901.
Robison, S.H., and Bradley, W.G. (1984). DNA damage and chronic neuronal
degenerations. J. Neurol. Sci. 64, 11–20.
Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A.,
Donaldson, D., Goto, J., O’Regan, J.P., Deng, H.X., et al. (1993). Mutations in
Cu/Zn superoxide dismutase gene are associated with familial amyotrophic
lateral sclerosis. Nature 362, 59–62.
Sampaio-Marques, B., Felgueiras, C., Silva, A., Rodrigues, M., Tenreiro, S.,
Franssens, V., Reichert, A.S., Outeiro, T.F., Winderickx, J., and Ludovico, P.
(2012). SNCA (a-synuclein)-induced toxicity in yeast cells is dependent on
sirtuin 2 (Sir2)-mediated mitophagy. Autophagy 8, 1494–1509.
Sasaki, T., Kim, H.J., Kobayashi, M., Kitamura, Y.I., Yokota-Hashimoto, H.,
Shiuchi, T., Minokoshi, Y., and Kitamura, T. (2010). Induction of hypothalamic
Sirt1 leads to cessation of feeding via agouti-related peptide. Endocrinology
151, 2556–2566.
Satoh, A., Brace, C.S., Ben-Josef, G., West, T., Wozniak, D.F., Holtzman,
D.M., Herzog, E.D., and Imai, S. (2010). SIRT1 promotes the central adaptive
response to diet restriction through activation of the dorsomedial and lateral
nuclei of the hypothalamus. J. Neurosci. 30, 10220–10232.482 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.Satoh, A., Brace, C.S., Rensing, N., Cliften, P., Wozniak, D.F., Herzog, E.D.,
Yamada, K.A., and Imai, S. (2013). Sirt1 extends life span and delays aging
in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell
Metab. 18, 416–430.
Schwer, B., North, B.J., Frye, R.A., Ott, M., and Verdin, E. (2002). The human
silent information regulator (Sir)2 homologue hSIRT3 is amitochondrial nicotin-
amide adenine dinucleotide-dependent deacetylase. J. Cell Biol. 158,
647–657.
Seo, J.S., Moon, M.H., Jeong, J.K., Seol, J.W., Lee, Y.J., Park, B.H., and Park,
S.Y. (2012). SIRT1, a histone deacetylase, regulates prion protein-induced
neuronal cell death. Neurobiol. Aging 33, 1110–1120.
Shindler, K.S., Ventura, E., Rex, T.S., Elliott, P., and Rostami, A. (2007). SIRT1
activation confers neuroprotection in experimental optic neuritis. Invest.
Ophthalmol. Vis. Sci. 48, 3602–3609.
Shindler, K.S., Ventura, E., Dutt, M., Elliott, P., Fitzgerald, D.C., and Rostami,
A. (2010). Oral resveratrol reduces neuronal damage in a model of multiple
sclerosis. J. Neuroophthalmol. 30, 328–339.
Shuto, T., Kuroiwa, M., Koga, Y., Kawahara, Y., Sotogaku, N., Toyomasu,
K., and Nishi, A. (2013). Acute effects of resveratrol to enhance cocaine-
induced dopamine neurotransmission in the striatum. Neurosci. Lett. 542,
107–112.
Singh, N.P., Hegde, V.L., Hofseth, L.J., Nagarkatti, M., and Nagarkatti, P.
(2007). Resveratrol (trans-3,5,40-trihydroxystilbene) ameliorates experimental
allergic encephalomyelitis, primarily via induction of apoptosis in T cells
involving activation of aryl hydrocarbon receptor and estrogen receptor.
Mol. Pharmacol. 72, 1508–1521.
Smith, J.S., Brachmann, C.B., Celic, I., Kenna, M.A., Muhammad, S., Starai,
V.J., Avalos, J.L., Escalante-Semerena, J.C., Grubmeyer, C., Wolberger, C.,
et al. (2000). A phylogenetically conserved NAD+-dependent protein deacety-
lase activity in the Sir2 protein family. Proc. Natl. Acad. Sci. USA 97, 6658–
6663.
Someya, S., Yu, W., Hallows, W.C., Xu, J., Vann, J.M., Leeuwenburgh, C.,
Tanokura, M., Denu, J.M., and Prolla, T.A. (2010). Sirt3 mediates reduction
of oxidative damage and prevention of age-related hearing loss under caloric
restriction. Cell 143, 802–812.
Sosa-Ortiz, A.L., Acosta-Castillo, I., and Prince, M.J. (2012). Epidemiology of
dementias and Alzheimer’s disease. Arch. Med. Res. 43, 600–608.
Sugino, T., Maruyama, M., Tanno, M., Kuno, A., Houkin, K., and Horio, Y.
(2010). Protein deacetylase SIRT1 in the cytoplasm promotes nerve
growth factor-induced neurite outgrowth in PC12 cells. FEBS Lett. 584,
2821–2826.
Sun, A.Y., Draczynska-Lusiak, B., and Sun, G.Y. (2001). Oxidized lipoproteins,
beta amyloid peptides and Alzheimer’s disease. Neurotox. Res. 3, 167–178.
Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., and Horio, Y. (2007).
Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase
SIRT1. J. Biol. Chem. 282, 6823–6832.
Tanny, J.C., Dowd, G.J., Huang, J., Hilz, H., and Moazed, D. (1999). An enzy-
matic activity in the yeast Sir2 protein that is essential for gene silencing. Cell
99, 735–745.
Vakhrusheva, O., Smolka, C., Gajawada, P., Kostin, S., Boettger, T., Kubin, T.,
Braun, T., and Bober, E. (2008). Sirt7 increases stress resistance of cardio-
myocytes and prevents apoptosis and inflammatory cardiomyopathy in
mice. Circ. Res. 102, 703–710.
van Ham, T.J., Thijssen, K.L., Breitling, R., Hofstra, R.M., Plasterk, R.H.,
and Nollen, E.A. (2008). C. elegans model identifies genetic modifiers
of alpha-synuclein inclusion formation during aging. PLoS Genet. 4,
e1000027.
Vela´squez, D.A., Martı´nez, G., Romero, A., Va´zquez, M.J., Boit, K.D., Dopeso-
Reyes, I.G., Lo´pez, M., Vidal, A., Nogueiras, R., and Die´guez, C. (2011). The
central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin.
Diabetes 60, 1177–1185.
Vingtdeux, V., Giliberto, L., Zhao, H., Chandakkar, P., Wu, Q., Simon, J.E.,
Janle, E.M., Lobo, J., Ferruzzi, M.G., Davies, P., and Marambaud, P. (2010).
Neuron
ReviewAMP-activated protein kinase signaling activation by resveratrol modulates
amyloid-beta peptide metabolism. J. Biol. Chem. 285, 9100–9113.
Wang, J., Zhang, Y., Tang, L., Zhang, N., and Fan, D. (2011). Protective effects
of resveratrol through the up-regulation of SIRT1 expression in the mutant
hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic
lateral sclerosis. Neurosci. Lett. 503, 250–255.
Wauters, E., Sanchez-Arevalo Lobo, V.J., Pinho, A.V., Mawson, A., Herranz,
D., Wu, J., Cowley, M.J., Colvin, E.K., Njicop, E.N., Sutherland, R.L., et al.
(2013). Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer
cell viability in pancreatic cancer. Cancer Res. 73, 2357–2367.
Westerheide, S.D., Anckar, J., Stevens, S.M., Jr., Sistonen, L., and Morimoto,
R.I. (2009). Stress-inducible regulation of heat shock factor 1 by the deacety-
lase SIRT1. Science 323, 1063–1066.Wu, Y., Li, X., Zhu, J.X., Xie, W., Le, W., Fan, Z., Jankovic, J., and Pan, T.
(2011). Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of
Parkinson’s disease. Neurosignals 19, 163–174.
Ya´n˜ez, M., Gala´n, L., Matı´as-Guiu, J., Vela, A., Guerrero, A., and Garcı´a, A.G.
(2011). CSF from amyotrophic lateral sclerosis patients produces glutamate
independent death of rat motor brain cortical neurons: protection by resvera-
trol but not riluzole. Brain Res. 1423, 77–86.
Yoshino, J., Mills, K.F., Yoon, M.J., and Imai, S. (2011). Nicotinamide mononu-
cleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and
age-induced diabetes in mice. Cell Metab. 14, 528–536.
Zhao, Y.N., Li, W.F., Li, F., Zhang, Z., Dai, Y.D., Xu, A.L., Qi, C., Gao, J.M., and
Gao, J. (2013). Resveratrol improves learning and memory in normally aged
mice through microRNA-CREB pathway. Biochem. Biophys. Res. Commun.
435, 597–602.Neuron 81, February 5, 2014 ª2014 Elsevier Inc. 483
